publication date: Oct. 10, 2014


html Regents.html

By Matthew Bin Han Ong

The University of Texas System Board of Regents has—in response to the threat of censure by an external group—voted to continue support of MD Anderson Cancer Center’s seven-year term tenure system.

The board convened a special meeting Oct. 3 to address an investigation of MD Anderson by the American Association of University Professors, an academic freedom and governance group that has criticized the institution’s lack of a lifetime tenure system (The Cancer Letter, Sept. 19).

The motion, made by Regent Bobby Stillwell and seconded by Regent Wallace Hall, reads:

“In recognition of the unique mission and international leadership of The University of Texas MD Anderson Cancer Center in the fight against cancer, I move that the Board voice strong support for the outstanding work of the institution’s faculty, staff and administration.

“I also move that the Board acknowledge appreciation for the work of the students, residents, and fellows in training and for the trust shown by the patients receiving care at UT MD Anderson.

“I move that the UT System Board of Regents vote to confirm its continued support for the authorization to award 7-year term tenure to faculty at The University of Texas MD Anderson Cancer Center, as the award of term tenure has helped to successfully elevate the institution to international recognition and success in delivering the best possible treatment and prevention against cancer.

“And, I further move that the Board support the position taken by UT MD Anderson in response to the recent challenge to the institution’s implementation of policies approved … Continue reading 40-38 UT Board Announces Support for MD Anderson Tenure System

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.